Tretinoin Market Size, Share and Global Trend By Application (Acne, Acute Promyelocytic Leukemia (APL)), By Strength (0.025%, 0.01%, 0.05%, 0.1%), By Distribution Channel (Hospitals & Clinics Pharmacies, Retail Pharmacies, Online Pharmacies), By Route of administration (Topical Applications, Oral), Regional Forecast, 2024-2032

Tretinoin also referred to as all-trans retinoic acid (ATRA), is a medication that is utilized in the treatment of mainly two disorders: acne and acute promyelocytic leukemia. Tretinoin is generally found in two forms: topical creams or gels used for the treatment of acne and in the form of oral medications, used for the treatment of acute promyelocytic leukemia.

Tretinoin is instrumental in the treatment of acute promyelocytic leukemia because it tries to induce remission in the patients diagnosed with the disorder. The FDA approval of several tretinoin formulations have led to a number of product offerings containing tretinoin because clinical trials have proved the efficacy for the treatment of acne, one of the most common dermatological disorders. In August 2018, the Food and Drug Administration (FDA), approved the once-daily tretinoin product called Altreno from Ortho Dermatologics for the treatment of acne in patients aged nine years or older. This product offering is the first ever tretinoin product to be available in the form of a lotion. 

One of the key market drivers for this market is the high prevalence of acne as a dermatological condition worldwide, combined with the current products in the market and the newly launched products in a variety of strengths and also, forms. According to the American Academy of Dermatology (AAD), it was estimated that in the U.S., acne is the most common skin condition and affects more than 50 million Americans every year and one of the most primary and efficient treatment is the administration of tretinoin. 

The factor that is expected to inhibit the growth of the market is the associated side effects with Tretinoin products. For instance, for the application of oral tretinoin products for the treatment of leukemia, there can be a number of adverse reactions such as leukocytosis and retinoic acid syndrome and other significant side effects such as thrombosis, liver damage, high lipids, and idiopathic intracranial hypertension, in children. 

Key Players Covered 

Some of the major companies that are present in the global Tretinoin market are Mylan Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Glaxosmithkline Inc., Janssen Pharmaceuticals, Inc., Bausch Health Companies Inc., Ortho Dermatologics, and other players. 

SEGMENTATION 

At present, treatment of acne accounts for the largest proportion of the market and this is expected to continue in the forecast period due to the prominently high usage of the tretinoin for the treatment of acne vulgaris compared to the treatment of Acute Promyelocytic Leukemia (APL). 

Key Insights 

• Prevalence of acne vulgaris & acute promyelocytic leukemia by key countries


• Regulatory scenario by key countries


• New product launches


• Advancements in research & development (R&D) 

Regional Analysis 

The global Tretinoin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for Tretinoin at present and they are expected to account for a large proportion of the market in the forecast period as well. One of the first commonly used tretinoin products were approved for use in the U.S. and the U.S. also a high proportion of the population suffering from acne vulgaris. In the Asia Pacific region, Japan is expected to provide the largest market opportunity. This is due to the presence of Chugai, a Japanese drug manufacturer controlled by F. Hoffmann-La Roche AG, who released Vesanoid (tretinoin) for the treatment of leukemia in Japan. 

Key Industry Developments

• In August 2018, Food and Drug Administration (FDA) approves the first ever tretinoin product offering in the form of lotion for the treatment of acne, Altreno from Ortho Dermatologics.


•  In January 2014, Valeant Pharmaceuticals (now Ortho Dermatologics) received the FDA approval for its product offering of Retin-A-Micro Microsphere 0.08% for the topical treatment of acne. The Retin-A-Micro line of tretinoin products is one of the most critical and crucial products for the treatment of acne vulgaris.


• An efficacy trial is underway for the low dose all trans-retinoic acid (tretinoin) for the patients suffering from Primary Sclerosing Cholangitis at Yale University in the U.S. The trial is currently in Phase 2, as of June, 2018.